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Background: Age and frailty from associated comorbidities signiﬁcantly inﬂuence choice of therapy in locally-advanced non-small cell
lung cancer (NSCLC). Performance status (PS) has been demonstrated
as a predictor of outcomes, while also inﬂuencing choice of therapy. In
surgical patients (pts), frailty as measured by the modiﬁed frailty index
(mFI) has been associated with worsening morbidity and mortality.
There is very limited data on using mFI in the non-surgical cancer
population.
Objectives: In a cohort of stage III NSCLC population, we aim to
investigate the utility of an 11-factor mFI in addition to age and PS to
predict oncological outcomes.
Methods: We retrospectively analyzed 97 stage III NSCLC pts treated
with concurrent chemoradiotherapy (CRT) between 2015-2019. An 11
factor mFI score was calculated based on the following variables:
ECOG score ≥ 2, impaired sensorium, diabetes, chronic lung disease,
myocardial infarction within 6 months, history of heart failure, coronary/cardiac disease, HTN on medication, history of transient ischemic
attack, stroke with deﬁcits, and peripheral vascular disease. KaplanMeier (KM) method with log-rank test was used to estimate overallsurvival (OS), progression free survival (PFS), and freedom-from local
failure (FFLF). Logistic regression was performed for toxicity (grade 2+
and 3+), with patients stratiﬁed by mFI score (non-frail vs frail with mFI
score 0-2 vs ≥ 3, respectively), median age (< 67 vs ≥ 67), and ECOG
PS (0-1 vs ≥ 2).
Results: The median age of the cohort was 67 years (range 50-87),
Caucasian (73%), with adenocarcinoma (51%). 53%, 41%, and 6% had
stage IIIA, IIIB, IIIC, respectively. The median mFI score for the entire
cohort was 2 (range 0-7). When stratiﬁed by mFI score (0-2 vs ≥ 3), there
was no statistically signiﬁcant difference in median RT dose (60 Gy each),
use of consolidation chemotherapy (53% vs 40%) or use of consolidation
immunotherapy (30% vs 23%). At a median follow-up of 17 months, KM
estimated median OS for the entire cohort was 21 months (0-81 months).
When stratiﬁed by mFI score, there was no signiﬁcant difference in 2-yr
OS (45.7% vs 49.6%, P = 0.81), PFS (30.1 vs 35.3%, P = 0.91), and FFLF
(77.2% vs 81.3%, P = 0.66). While age was not a signiﬁcant predictor of
2-yr OS, PFS, and FFLF, lower PS (0-1 vs ≥ 2) was associated with
improved 2-yr OS (50.8% vs 30.0%, P = 0.01) and PFS (33.2% vs 20.0%,
P = 0.03), but not FFLF (77.9% vs 83.3%, P = 0.45). Stratiﬁcation by mFI,
ECOG, and age was not predictive of the development of grade 2+ toxicity, severe grade 3+ toxicity or radiation pneumonitis on univariate and
multivariate logistic regression.
Conclusions: Contrary to results from surgical series, our retrospective
analysis did not demonstrate utility of mFI in predicting risk of toxicity
or survival/local failure in pts with stage III NSCLC treated with
curative chemoRT. Future efforts will need to explore the utility of
ECOG PS, mFI, and other metrics to help select patients and predict
outcomes.
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Background: Deﬁnitive hypofractionated radiation therapy (RT) has
demonstrated improved oncologic outcomes in patients with non-small
cell lung cancer (NSCLC). However, there remain concerns regarding
toxicity, and the optimal integration of accelerated RT with concurrent
systemic chemotherapy is unknown.
Objectives: We aimed to evaluate the outcomes and toxicities of
patients treated with deﬁnitive hypofractionated accelerated RT
(HART) with concurrent chemotherapy.
Methods: We retrospectively reviewed patients with Stage II-IV
NSCLC who underwent deﬁnitive HART with concurrent chemotherapy from 2012 to 2021 at our institution. HART was deﬁned as
doses greater than 2.2 Gy per fraction and radiation was delivered using
intensity modulated radiation therapy without a clinical treatment volume expansion or elective nodal coverage. Cumulative incidence of
locoregional recurrence (LRR), and distant metastases (DM) were calculated from the time of completion of RT with competing risk analysis.
Univariable analysis was conducted to identify predictors for pneumonitis. Overall survival (OS) was analyzed using Kaplan-Meier.
Results: A total of 50 patients were identiﬁed. Median follow-up
time was 15 months (range 0-97 months). Median age was 68 years
(range 34-80 years); 40% were female. 62% of the patients had
pulmonary disease at baseline. Two (4%) patients had stage II, 37
(74%) stage III, and 11 (22%) had stage IV disease. Median RT dose
was 65 Gy (range 49.5-69 Gy), and median dose per fraction was
2.75 Gy (range 2.4-3.5 Gy fractions). The most common systemic
therapy used was carboplatin with paclitaxel (56%). Median OS of
the cohort was 42 months (95% conﬁdence interval [CI] 30-not
reached). The 1-year cumulative incidence of LRR and DM was
7.5% (95% CI 1.9-18.4%) and 32.7% (95% CI 19.0-27%), respectively. The median lung V20, lung Dmean, was 15.44% (range 0.3229.47%) and 9 Gy (range 2.4-16.0 Gy), respectively. The median
heart V30 and heart Dmean was 1.5% (range 0-76.1%) and 4.2 Gy
(range 0.3-35.1 Gy), respectively. The median esophagus Dmax and
esophagus V60 was 56.7 Gy (range 6.1-72.6 Gy) and 0% (range
0-29.4%). The most common acute grade 1-2 toxicities were
esophagitis (44%) and fatigue (22%). No acute grade 3-4 toxicities
were observed. Six patients (12%) had their concurrent chemotherapy held. Pneumonitis was observed in 16% of patients and there
were no cases of late cardiac toxicities attributable to treatment.
Mean lung dose, lung V20 and fraction size were not associated with
pneumonitis on univariable analysis.
Conclusions: In select patients in whom we could achieve low doses to
organs at risk using highly conformal image guided techniques, deﬁnitive HART with concurrent chemotherapy achieved excellent local
control with low toxicities. These results are being used to inform a
prospective study on the safety and efﬁcacy of HART with concurrent
chemotherapy for select NSCLC patients.
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Background: The advent of screening chest computed tomography
(CT) for high-risk patients has increased the patient population presenting with early-stage small cell lung cancer (SCLC). While surgical
resection continues to be standard of care, stereotactic body radiation
therapy (SBRT) is an option for non-surgical candidates. Although the
effectiveness of PCI in patients with limited stage SCLC has been well
established, decreasing the brain metastasis incidence from approximately 70% to 30%, the role of PCI in early-stage SCLC (T1-T2) has
not been fully elucidated. This study reports our experience omitting
PCI in early-stage SCLC.
Objectives: This study reports our experience omitting PCI in earlystage SCLC.
Methods: Fourteen patients with early-stage SCLC, nine patients with
clinical stage I (T1) and ﬁve patients with stage IA (T2) SCLC, ranging
in age from 54-81 years old, treated with surgical resection or SBRT
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from July 2015 to May 2021 at our institution, were retrospectively
reviewed. Positron emission tomography (PET) was used in the staging
of 93% of patients. All patients had initial negative brain MRI and opted
not to receive PCI. 71% of the patients had brain scan surveillance for
follow-up. Risk factors including age, gender, and tumor size, were
analyzed for overall survival (OS), loco-regional recurrence (LRR), and
distant metastasis (DM) using the Log-rank test.
Results: With a median follow-up of 13 months (range 2-63), none of
our patients developed metastases to the brain. Adjuvant chemotherapy,
with a mean of 4 cycles (2-6) was administered to 13 out of 14 patients
(92%). The 2-year OS, LRR and DM estimates were 47% [95% CI
(0.14, 0.75)], 57% [95% CI (0.19, 0.82)], and 51% [95% CI (0.17,
0.77)], respectively. The OS and the frequency of LRR were not found
to be correlated with age, gender, or tumor size. DM was signiﬁcantly
higher in males vs females (P = 0.016).
Conclusions: Our experience in patients with Stage I-IIA SCLC
treated with surgery or SBRT did not demonstrate any development of
brain metastases. As PCI carries long term risks of neurotoxicity, close
surveillance with regular brain imaging may be a reasonable alternative. Adjuvant systemic therapy remains an important component of
treatment.
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Background: Adoption of magnetic resonance-guided radiation therapy (MRgRT) has increased in recent years. The 0.35T MR-Linac is
currently the only clinical device that provides intrafraction cine-MR
imaging, automated soft tissue tracking, automatic beam exclusion
gating, and on-table adaptive replanning. These unique abilities can
reduce toxicity while also allowing for safe dose escalation in fewer
fractions compared to CT-based radiation therapy.
Objectives: We report on a single-institution clinical experience
using MRgRT on a 0.35T MR-Linac system over the past 3.5 years.
Methods: We reviewed patterns of utilization at our institution of
patients treated on a 0.35T MR-Linac between April 2018 and
December 2021. On-table adaptive replanning began in September
2018. No patient was treated with implanted ﬁducial markers. Treatments were preferentially in breath hold, or otherwise free breathing
gating, and therefore an internal target volume (ITV) was never used.
Setup margins (SM) were typically isotropic 3 mm, or otherwise 5 mm.
Results: We evaluated 415 patients treated to 483 lesions. Median age
was 69 years (range 7-92 years). The most frequently treated sites were
pancreas (n = 135; 28%), lung (n = 102; 21%), abdominal/pelvic lymph
nodes (n = 72; 15%), liver (n = 49; 10%), adrenal gland (n = 44; 9%),
prostate (n = 16; 3%), and esophagus (n = 13; 3%). The greatest relative
increase in utilization was for adrenal gland metastases (2018-2019:
5%; 2020-2021: 12%). The median prescription dose was 50 Gy in 5
fractions. Compared to 2018-2019, patients in 2020-2021 were more
often treated in 1-6 fractions (85% vs. 74%) and less often > 15 fractions (17% vs. 5%). The percentage of delivered fractions that were
adapted sharply increased from 7% in 2018 to 24% in 2019, 40% in
2020, and 40% in 2021.
Conclusions: Despite offering multiple advanced photon therapy systems and pencil beam proton therapy at our institution, we have seen
remarkable growth of our MRgRT program. Our MR-Linac has predominantly been used for ablative, coarse hypofractionated treatment of
mobile tumors, especially those in challenging anatomic locations (e.g.,
pancreas, lymph nodes) for which on-table adaptive replanning offers
substantial clinical beneﬁt by ensuring that organ-at-risk constraints are
met despite potentially large interfraction and intrafraction anatomic
changes.
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Shraddha Dalwadi, MD1, Jarey Wang, MD1, Michelle Ludwig, MD,1;
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Background: Despite radiation oncology being a critical component of
cancer care, few students are exposed to the ﬁeld and its technical
elements as part of their undergraduate medical education.
Objectives: The purpose of this project was to evaluate student comfort
with contouring after completion of a virtual curriculum as part of a
2-week clinical elective.
Methods: Clinical students were enrolled in a 2-week elective that
integrated both clinical activities and self-directed learning through
virtual contouring modules. The virtual curriculum was designed
around three modules available on EduCase. A survey was conducted
after completion of the modules to assess their efﬁcacy in increasing
understanding of basic contouring skills. To assess differences in preand post-course survey results, we used Student’s two-sided paired
t-test.
Results: 10/13 students completed the survey at the end of the course. 8
students had no prior exposure to contouring software. Overall, there
was a signiﬁcant increase in comfort level using radiation planning
software (P = 3.4e-3) as well as ability to ﬁnd relevant contouring references (P = 2.6e-4). Knowledge of the anatomy and contouring principles also improved for the three modules: eye and brain (P = 8.5e-5),
high grade glioma (1.7e-4), and head and neck nodal stations (4.0e-4).
Conclusions: Integration of a self-directed virtual contouring experience into a clinical elective was helpful for improving student understanding of this technical aspect of radiation oncology.

(P48) Leading Self Through Communication: A Novel Skills
Workshop
Austin Sim, MD, JD1, Lauren Linkowski, BS2, Barbara Lubrano di
Ciccone, MD3, Edmondo Robinson, MD, MS, MBA4, Julian Sanchez,
MD5, Jessica Frakes, MD1, Stephen Rosenberg, MD, MS1, Sarah
Hoffe, MD4; 1Department of Radiation Oncology, H. Lee Mofﬁtt
Cancer Center & Research Institute, 2University of South Florida,
3
Department of Supportive Care Medicine, H. Lee Mofﬁtt Cancer
Center & Research Institute, 4Mofﬁtt Cancer Center, 5Department of
Gastrointestinal Oncology, H. Lee Mofﬁtt Cancer Center & Research
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Background: Competency in communication has been a focus of the
Accreditation Council for Graduate Medical Education (ACGME)
(Batalden P, Health Aff 2002), especially at the patient bedside (Makoul
G, JAMA 2003). Residency programs have more recently sought to
integrate these and other leadership competencies into training as formalized curricula using various frameworks (Blumenthal D, Acad Med
2012). A commonly used framework is the Emotional Intelligence
Model, which has “leading self” as one of the core tenets (Goleman D,
Harv Bus Rev 2017). Our residency program has developed a unique
longitudinal leadership development course to incorporate such training
(Song E, J Cancer Educ 2021). As a new iteration of this curriculum, we
implemented a novel skills workshop in two communications scenarios.
Objectives: Within our longitudinal leadership development course that
meets monthly, we sought to improve communication skills conveying
complex information outside of traditional clinical and scientiﬁc fora to
a lay audience.
Methods: We collaborated with clinical faculty with formal communications and media training, as well as with faculty from the university
Communications Department for this three-part workshop. Residents
were ﬁrst assigned to deliver a ﬁve-minute grant “elevator pitch” to a
simulated Foundation Board via videoconferencing. These pitches were
recorded and reviewed with expert commentary in the second session.
The ﬁnal session required residents to go “on camera” with a simulated
news reporter to answer questions about their research for a lay
audience.
Results: Communications faculty provided immediate feedback on
delivery (tone, pitch, body language), while clinicians focused on
appropriateness of content. The recorded pitches were then reviewed
by the residents with additional clinical faculty. On qualitative interviews, participating residents noted unconscious mannerisms,
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